These findings in melanomas resistant to MAPK pathway blockade, as well as our results from this study, suggest a potential avenue not only for FAK/RAF/MEK inhibition in combination in patients with BRAFV600E-driven CM who have progressed on targeted therapy but also for those with brain metastases or at risk for developing brain metastases. Here, MAP2K7 is linked to melanoma.